scholarly journals A neonate with Say–Barber–Biesecker–Young–Simpson syndrome with a novel pathogenic mutation in KAT6B gene: A case report

2021 ◽  
Vol 18 (2) ◽  
pp. 147-151
Author(s):  
Ji Hye Shin ◽  
Han Hyuk Lim ◽  
Mi Hyeon Gang ◽  
Seon Young Kim ◽  
Shin-seung Yang ◽  
...  
2016 ◽  
Vol 146 (suppl_1) ◽  
Author(s):  
Jose Scarpa Carniello ◽  
Chuanyong Lu ◽  
Jacqueline Skelton ◽  
Ning Chen ◽  
Alejandro Zuretti

2021 ◽  
Vol 11 ◽  
Author(s):  
Haiyan Bai ◽  
Xia Xue ◽  
Li Tian ◽  
Xi Tong Liu ◽  
Qian Li

Hemophilia A is an X-linked recessive bleeding disorder caused by various types of pathological defects in the factor VIII gene (F8/FVIII). Preimplantation genetic testing for monogenic disease (PGT-M) is a powerful tool to tackle the transmission of monogenic inherited disorders from generation to generation. In our case, a mutation in F8 had passed through female carriers in a hemophilia A family and resulted in two male patients with hemophilia A. To identify the etiological genetic variants of F8, next-generation sequencing (NGS) was used for chromosome copy number variation detection, Sanger sequencing to verify mutation sites, single nucleotide polymorphism (SNP) for site amplification, and sequencing to validate the genetic linkage. Finally, a novel missense mutation, p. (Phe690Leu)/c.2070C > A, occurring in exon 13 of F8, was screened out as a pathogenic mutation. Following this, an F8 normal euploid blastocyst was transferred. At the 18th week, the pregnant mother underwent amniocentesis, NGS, Sanger sequencing, and SNP typing that further confirmed that the fetus had a healthy genotype. After delivery, a neonatal blood sample was sent for FVIII concentration detection, and the result established that the FVIII protein was rescued to a nearly average level. We first identified a new type of pathogenic mutation in F8, which has not been previously reported, selected a genetically healthy progeny for an affected family, and provided valuable knowledge of the diagnosis and treatment of hemophilia A.


Neurocase ◽  
2013 ◽  
Vol 19 (1) ◽  
pp. 41-53 ◽  
Author(s):  
Robert Rusina ◽  
Jindřich Fiala ◽  
Karel Holada ◽  
Milada Matějčková ◽  
Jana Nováková ◽  
...  

2014 ◽  
Vol 7 (1) ◽  
pp. 487 ◽  
Author(s):  
Thais Cuperman ◽  
Stephanie A Fernandes ◽  
Naila CV Lourenço ◽  
Lydia U Yamamoto ◽  
Helga CA Silva ◽  
...  

2014 ◽  
Vol 7 (1) ◽  
Author(s):  
Amir MI Babiker ◽  
Iman Al Gadi ◽  
Nasir AM Al-Jurayyan ◽  
Abdulrahman MH Al Nemri ◽  
AliAbdu N Al haboob ◽  
...  

2011 ◽  
Vol 300 (1-2) ◽  
pp. 191-193 ◽  
Author(s):  
Anne Waschbisch ◽  
Bastian Volbers ◽  
Tobias Struffert ◽  
Juliane Hoyer ◽  
Stefan Schwab ◽  
...  

Author(s):  
Caroline Guth de Freitas Batista de Moraes ◽  
Liya Regina Mikami ◽  
Lilian Pereira Ferrari ◽  
João Bosco Pesquero ◽  
Herberto José Chong-Neto ◽  
...  

Abstract Objective To verify the efficacy of short-term prophylaxis for vaginal or cesarean section childbirth with plasma-derived C1-inhibitor concentrate in pregnant women. They should have hereditary angioedema (HAE) and normal plasma C1-inhibitor. Methods Case report of pregnant women diagnosed with HAE with normal C1-inhibitor who had been treated with intravenous C1-inhibitor concentrate for prophylaxis of angioedema attacks when hospitalized for delivery. The exon 9 of the Factor 12 (F12) genotyping gene was performed by automatic sequencing in all patients. Results Three cases of pregnant women with HAE with normal serum level of C1-inhibitor are reported. The genetic test detected the presence of a pathogenic mutation in the F12 gene. Deliveries occurred uneventfully and patients had no HAE symptoms in the following 72 hours. Conclusion C1-inhibitor concentrate could be useful to prevent angioedema attacks during and after delivery.


2020 ◽  
Vol 1 (2) ◽  
pp. 20-21
Author(s):  
Sara Hooshmand ◽  
Raghav Govindarajan

Introduction: Myosin heavy chain 7 (MYH7)-related myopathies have variable clinical features and onsets and are emerging as a group of muscle diseases that affect a wide range of age groups. While individuals with (MYH7)-related myopathies will present with cardiac or skeletal involvement, it is less common to see cardiac and skeletal involvement occurring in a single individual.  Case Report: A 66-year old right-handed woman presented to the clinic for progressive ascending weakness, weight loss, and severe dysphagia. Symptoms first arose when the patient was in her 20s when she reported lower extremity weakness. Over the years, the weakness has ascended, and today the patient is unable to raise her arms. The patient has a family history of muscle disease, but testing has not been done. Neurological examination of mental status and cranial nerve were intact. Shoulder abduction, flexion, and extension was 2/5 bilaterally. Hip flexion was 3/5, and foot dorsiflexion was 2/5 bilaterally. There was no elevation of serum creatinine, and EMG showed myopathic process. Muscle biopsy of the deltoid revealed a myopathic changes with mini cores. EKG reveals first degree AV block with anterior ischemia and echocardiogram showing features of dilated cardiomyopathy. The genetic panel revealed c.4522_c.4524del (p.Glu1508del) resulting in pathogenic mutation of MYH7 leading to scapuloperoneal myopathy. Discussion: This case report illustrates the variability in clinical presentation of adult-onset MYH7 myopathy. MYH7 gene-related myopathies have notable clinical variability that can lead to the missed or late diagnosis of this progressive myopathy. While our case highlights the pertinent family history and co-existing cardiac involvement that is strongly associated with MYH7 related myopathy, it also illustrates further cases of MYH7 mutations causing both cardiac and skeletal muscle disease.


2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Adrian Giucă ◽  
Cristina Mitu ◽  
Bogdan Ovidiu Popescu ◽  
Alexandra Eugenia Bastian ◽  
Răzvan Capşa ◽  
...  

Abstract Background Hypertrophic cardiomyopathy (HCM) is a genetic disorder mostly caused by sarcomeric gene mutations, but almost 10% of cases are attributed to inherited metabolic and neuromuscular disorders. First described in 2008 in an American-Italian family with scapuloperoneal myopathy, FHL1 gene encodes four-and-a-half LIM domains 1 proteins which are involved in sarcomere formation, assembly and biomechanical stress sensing both in cardiac and skeletal muscle, and its mutations are responsible for a large spectrum of neuromuscular disorders (mostly myopathies) and cardiac disease, represented by HCM, either isolated, or in conjunction with neurologic and skeletal muscle impairment. We thereby report a novel mutation variant in FHL1 structure, associated with HCM and type 6 Emery-Dreifuss muscular dystrophy (EDMD). Case presentation We describe the case of a 40 year old male patient, who was referred to our department for evaluation in the setting of NYHA II heart failure symptoms and was found to have HCM. The elevated muscular enzymes raised the suspicion of a neuromuscular disease. Rigid low spine and wasting of deltoidus, supraspinatus, infraspinatus and calf muscles were described by the neurological examination. Electromyography and muscle biopsy found evidence of chronic myopathy. Diagnosis work-up was completed by next-generation sequencing genetic testing which found a likely pathogenic mutation in the FHL1 gene (c.157-1G > A, hemizygous) involved in the development of X-linked EDMD type 6. Conclusion This case report highlights the importance of multimodality diagnostic approach in a patient with a neuromuscular disorder and associated hypertrophic cardiomyopathy by identifying a novel mutation variant in FHL1 gene. Raising awareness of non-sarcomeric gene mutations which can lead to HCM is fundamental, because of diagnostic and clinical risk stratification challenges.


2020 ◽  
Vol 18 (5) ◽  
pp. 143-145
Author(s):  
Z. G. KHAYATOVA ◽  
◽  
Z. A. ZALYALOVA ◽  
A. Yu. KAZANTSEV ◽  
T. V. MATVEYEVA ◽  
...  

The authors present a case-report of genetically tested dopa-responsive dystonia, also known as Segawa’s syndrome, in a 32-year-old woman. The genetic forms and their clinical presentation are described. Symptoms began in early childhood with running disability. The patient’s first complaint was twisting of her toes during walking when she was 12 years old. The condition remained stable up to 20 y. o., when some improvement was noticed. Symptoms progressed with involvement of upper limbs at the age of 25. By the age of 32 the patient was directed to Movement Disorders Clinic, where Dopa-responsive dystonia was suspected. The manifestations were dramatically responsive to low doses of levodopa-carbidopa, confirming the diagnosis of dopa-responsive dystonia. The genetic test identified a GCH1 (chr14:55369161G>A) pathogenic mutation.


Sign in / Sign up

Export Citation Format

Share Document